Hiperpotasemia

1. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in 1 hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-24.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect 2 of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
3. Perazella MA. Drug-induced hyperkalemia: old culprits and new 3 offenders. Am J Med 2000;109:307-14.
4. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. 4 Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
5. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. 5 Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
6. Hollander-Rodgriguez JC, Calvert JF Jr. Hyperkalemia. 6 Am Fam Physician 2006;73:283-90.
7. Ahuja T, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon 7 A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000;20:268-72.
8. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using 8 angiotensin-converting enzyme inhibitors. Arch Intern Med 1998;158:26-32.
9. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalemia in congestive heart 9 failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9.
10. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of 10 spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211-4.
11. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How 11 prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303.
12. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone 12 antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009;(3):CD007004.
13. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of 13 nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111:64-7.
14. Slovis C, Jenkins R. ABC of clinical electrocardiography: conditions not 14 primarily affecting the heart. BMJ 2002;324:1320-3.
15. Ethier JH, Kamel KS, Magner PO, Lemann J, Halperin ML. The transtubular 15 potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kid Dis 1990;4:309-15.
16. Kim H-J, Han S-W. Therapeutic approach to hyperkalaemia 16 Nephron 2002;92(suppl 1):33-40.
17. Charytan D, Goldfarb DS. Indications for hospitalization of patients with 17 hyperkalemia. Arch Intern Med 2000;160:1605-11.
18. Greenberg A. Hyperkalaemia: treatment options. 18 Semin Nephrol 1998;18:46-57.
19. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency 19 interventions for hyperkalaemia. Cochrane Database Syst Rev 2005;(2):CD003235.
20. Davey M. Calcium for hyperkalemia in digoxin toxicity. 20 Emerg Med J 2002;19:183.
21. Allon M, Shanklin N. Effect of bicarbonate administration on plasma 21 potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis 1996;28:508-14.
22. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. 22 Nephrol Dial Transplant 2003;18:2215-8.